Adulhelm P3 trial data on Alzheimer’s drug inconsistent - Japanese health ministry

A committee of the Japanese health ministry cited inconsistent results from global late-stage studies for Adulhelm that they said made it difficult to evaluate its efficacy. Adulhelm, developed by Biogen (NASDAQ:BIIB) and Tokyo-based Eisai (OTCPK:ESALY), was approved by the FDA for Alzheimer’s disease in June.

In a statement on Wednesday, the panel also noted a lack of clinical significance of the treatment’s ability to reduce plaques on the brain, a hallmark of Alzheimer’s pathology. According to Reuters, the panel has said it will conduct a review once again upon submission of new data.

Read more: https://seekingalpha.com/news/3782605-biogen-eisai-trial-data-on-alzheimers-drug-inconsistent-japanese-health-ministry